Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

OSR Health Q3 2026 Results: Net Loss of $1.61M, Loss Narrows

OSR Health, Inc. reported a net loss of $6.38 million for the nine months ended September 30, 2026, an improvement from the $19.81 million loss in the prior year period. Total assets increased to $185.8 million, primarily driven by growth in intangible assets and goodwill following business combinations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.50.6
Gross profit0.00.3
Profit before tax-2.4-4.5
Net income-1.6-2.1
EPS (diluted, $ a share)$-0.05$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-16.4%
Gross margin7.2%
Source

10-Q filed with the SEC, OTC: OSRH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

OSR Health, Inc.: key numbers

Share price
$0.1165Close, Nov 16
Market cap
$4.11M
Shares outstanding
35.26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from OSR Health, Inc.

All →
8:38 AM ET 8-K
Other 8-K Filing

OSR Health Other 8-K Filing

Shinhan Accounting Corporation resigned as OSR Health's independent auditor on November 6, 2026, citing overdue fees that created a potential independence threat. The company's previous financial reports included a going concern warning and identified material weaknesses in internal control over financial reporting. The Audit Committee has accepted the resignation and is currently seeking a successor accounting firm.

Counterparty
Shinhan Accounting Corporation
9:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice

OSR Health Nasdaq/NYSE Compliance Notice

OSR Health received a written decision from the Nasdaq Hearings Panel on October 23, 2026, denying its request for continued listing and determining to delist the company's securities. The delisting follows the company's failure to regain compliance with the $1.00 minimum bid price requirement, and its securities will continue to be quoted on the over-the-counter market under the symbols OSRH and OSRHW.

Counterparty
The Nasdaq Stock Market LLC
9:18 AM ET 8-K
Loan & Debt

OSR Health $15M Debt Financing with BCM Europe AG

OSR Health entered into an amendment to its license agreement with BCM Europe AG to add a convertible note option as an alternative settlement for a $15 million equity put option. The change was triggered by a Nasdaq delisting determination and allows the company to issue up to $15 million in convertible notes in four tranches with fixed conversion prices ranging from $2.00 to $5.00 per share.

Value
$15M
Counterparty
BCM Europe AG
4:32 PM ET 8-K
Leadership Change

OSR Health Leadership Change

Dr. Constance Hoefer resigned as Chief Scientific Officer of OSR Health, Inc., effective September 30, 2026. The company stated the departure was not due to any dispute or disagreement regarding operations, policies, or practices.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.